“He’s a hero, in every sense of the word,” Wilson County Schools wrote of Lebanon High School student-athlete Jayden Bailey ...
Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...
Innovation is urgent and direly needed as pediatric cancers remain the leading disease-based cause of pediatric death in the United States. OS Therapies is empowered to continue its groundbreaking ...
Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data ...
Backed by a $15 million investment, families, funders, and researchers unite to advance long-awaited breakthroughs against this deadly childhood bone cancer "This Break Through Cancer project brings a ...
February 17, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today provided a global regulatory update for ...
Researchers published a new study, “Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution,” in Cell that they say solves the mystery of what drives the genomic ...
Scientists at St. Jude Children’s Research Hospital report that they have identified a way to improve CAR T-cell homing for osteosarcoma. Their study “Redirecting B7-H3.CAR T cells to chemokines ...
A major driver of the bone cancer osteosarcoma has been discovered by researchers from UCL, EMBL EBI and the Royal National Orthopaedic Hospital, providing insights that could help to predict cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results